A Phase 3 Study Evaluating the Pharmacokinetics, Safety, and Tolerability of VX-659/TEZ/IVA Triple Combination Therapy in Cystic Fibrosis Subjects 6 Through 11 Years of Age
Phase of Trial: Phase III
Latest Information Update: 04 Sep 2019
Price : $35 *
At a glance
- Drugs Ivacaftor (Primary) ; Ivacaftor/tezacaftor/VX-659 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Pharmacokinetics; Registrational
- Sponsors Vertex Pharmaceuticals
- 21 Aug 2019 Status changed from recruiting to discontinued.
- 29 Aug 2018 Status changed from not yet recruiting to recruiting.
- 23 Aug 2018 New trial record